Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for BX004 in Cystic Fibrosis, P. aeruginosa lung infections. The expected timing is based on the latest available company guidance and may change.
7/14/25- Trial initiated. 8/19/25- FDA placed clinical hold. 10/17/25- Responded to FDA queries. EU enrollment ongoing. 11/25/25– DMC supports revised dosing. Topline Q2 2026. 12/08/25:- CF Ph2b BX004 trial discontinued after safety review and internal analysis.
Verification
Confirm timing and program details against the company announcement or filing.